J&J hits main goal in early-stage trial for drug delivery system

AI Briefing

• – J&J's Erda-iDRS drug delivery system meets main goal in Phase 1 trial for bladder cancer.
• – The trial is a significant milestone for the company's oncology portfolio.
• – J&J's stock is expected to see a positive reaction to the news.